99 related articles for article (PubMed ID: 11277328)
21. Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer.
Goodell V; Salazar LG; Urban N; Drescher CW; Gray H; Swensen RE; McIntosh MW; Disis ML
J Clin Oncol; 2006 Feb; 24(5):762-8. PubMed ID: 16391298
[TBL] [Abstract][Full Text] [Related]
22. Expression of the p53 family in lung cancer.
Uramoto H; Sugio K; Oyama T; Nakata S; Ono K; Nozoe T; Yasumoto K
Anticancer Res; 2006; 26(3A):1785-90. PubMed ID: 16827107
[TBL] [Abstract][Full Text] [Related]
23. Detection of p53 autoantibodies in sera of gastric cancer patients and their prognostic relevance.
Würl P; Weigmann F; Meye A; Fittkau M; Rose U; Berger D; Rath FW; Dralle H; Taubert H
Scand J Gastroenterol; 1997 Nov; 32(11):1147-51. PubMed ID: 9399397
[TBL] [Abstract][Full Text] [Related]
24. Clinical significance of serum P53 antibody in patients with gastric cancer.
Shiota G; Ishida M; Noguchi N; Takano Y; Oyama K; Okubo M; Katayama S; Harada K; Hori K; Ashida K; Kishimoto Y; Hosoda A; Suou T; Ito H; Kawasaki H
Res Commun Mol Pathol Pharmacol; 1998 Jan; 99(1):41-51. PubMed ID: 9523354
[TBL] [Abstract][Full Text] [Related]
25. Decreased expression of p12 is associated with more advanced tumor invasion in human gastric cancer tissues.
Choi MG; Sohn TS; Park SB; Paik YH; Noh JH; Kim KM; Park CK; Kim S
Eur Surg Res; 2009; 42(4):223-9. PubMed ID: 19279387
[TBL] [Abstract][Full Text] [Related]
26. Maspin in thyroid cancer: its relationship with p53 and clinical outcome.
Boltze C; Schneider-Stock R; Meyer F; Peters B; Quednow C; Hoang-Vu C; Roessner A
Oncol Rep; 2003; 10(6):1783-7. PubMed ID: 14534696
[TBL] [Abstract][Full Text] [Related]
27. Serum anti-p53 in relation to mutations across the entire translated p53 gene in colorectal carcinomas.
Forslund A; Kressner U; Lindmark G; Inganäs M; Lundholm K
Int J Oncol; 2001 Sep; 19(3):501-6. PubMed ID: 11494027
[TBL] [Abstract][Full Text] [Related]
28. p53 as a new prognostic factor for lymph node metastasis in penile carcinoma: analysis of 82 patients treated with amputation and bilateral lymphadenectomy.
Lopes A; Bezerra AL; Pinto CA; Serrano SV; de MellO CA; Villa LL
J Urol; 2002 Jul; 168(1):81-6. PubMed ID: 12050497
[TBL] [Abstract][Full Text] [Related]
29. Clinical significance of HLA class I heavy chain expression in patients with gastric cancer.
Ueda Y; Ishikawa K; Shiraishi N; Yokoyama S; Kitano S
J Surg Oncol; 2008 Apr; 97(5):451-5. PubMed ID: 18247377
[TBL] [Abstract][Full Text] [Related]
30. Expression of the antiapoptosis gene Survivin predicts poor prognosis of stage III gastric adenocarcinoma.
Song KY; Jung CK; Park WS; Park CH
Jpn J Clin Oncol; 2009 May; 39(5):290-6. PubMed ID: 19336448
[TBL] [Abstract][Full Text] [Related]
31. A proposed staging system for gastric carcinoid tumors based on an analysis of 1,543 patients.
Landry CS; Brock G; Scoggins CR; McMasters KM; Martin RC
Ann Surg Oncol; 2009 Jan; 16(1):51-60. PubMed ID: 18953609
[TBL] [Abstract][Full Text] [Related]
32. Detection of circulating gastric cancer cells in peripheral blood using real time quantitative RT-PCR.
Koga T; Tokunaga E; Sumiyoshi Y; Oki E; Oda S; Takahashi I; Kakeji Y; Baba H; Maehara Y
Hepatogastroenterology; 2008; 55(84):1131-5. PubMed ID: 18705345
[TBL] [Abstract][Full Text] [Related]
33. Survival of ovarian cancer patients overexpressing the tumour antigen p53 is diminished in case of MHC class I down-regulation.
Leffers N; Lambeck AJ; de Graeff P; Bijlsma AY; Daemen T; van der Zee AG; Nijman HW
Gynecol Oncol; 2008 Sep; 110(3):365-73. PubMed ID: 18571704
[TBL] [Abstract][Full Text] [Related]
34. Anti-P53 antibodies in Brazilian brain tumor patients.
Fonseca RF; Kawamura MT; Oliveira JA; Teixeira A; Alves G; Carvalho Mda G
Genet Mol Res; 2003 Jun; 2(2):185-90. PubMed ID: 14966683
[TBL] [Abstract][Full Text] [Related]
35. Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.
el-Ahmady O; el-Salahy E; Mahmoud M; Wahab MA; Eissa S; Khalifa A
Anticancer Res; 2002; 22(4):2493-9. PubMed ID: 12174951
[TBL] [Abstract][Full Text] [Related]
36. Prognostic use of growth characteristics of early gastric cancer and expression patterns of apoptotic, cell proliferation, and cell adhesion proteins.
Pan W; Ishii H; Ebihara Y; Gobe G
J Surg Oncol; 2003 Feb; 82(2):104-10. PubMed ID: 12561066
[TBL] [Abstract][Full Text] [Related]
37. Maspin expression in early oral tongue cancer and its relation to expression of mutant-type p53 and vascular endothelial growth factor (VEGF).
Cho JH; Kim HS; Park CS; Kim JK; Jung KY; Shin BK; Kim HK
Oral Oncol; 2007 Mar; 43(3):272-7. PubMed ID: 17174141
[TBL] [Abstract][Full Text] [Related]
38. TP53 in gastric cancer: mutations in the l3 loop and LSH motif DNA-binding domains of TP53 predict poor outcome.
Migliavacca M; Ottini L; Bazan V; Agnese V; Corsale S; Macaluso M; Lupi R; Dardanoni G; Valerio MR; Pantuso G; Di Fede G; Tomasino RM; Gebbia N; Mariani-Costantini R; Russo A
J Cell Physiol; 2004 Sep; 200(3):476-85. PubMed ID: 15254976
[TBL] [Abstract][Full Text] [Related]
39. Prediction of sites of recurrence in gastric carcinoma using immunohistochemical parameters.
Saito H; Osaki T; Murakami D; Sakamoto T; Kanaji S; Ohro S; Tatebe S; Tsujitani S; Ikeguchi M
J Surg Oncol; 2007 Feb; 95(2):123-8. PubMed ID: 17262742
[TBL] [Abstract][Full Text] [Related]
40. Distribution of p53 mutations in esophageal and gastric carcinomas and the relationship with p53 expression.
Hanazono K; Natsugoe S; Stein HJ; Aikou T; Hoefler H; Siewert JR
Oncol Rep; 2006 Apr; 15(4):821-4. PubMed ID: 16525665
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
